{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:53Z","timestamp":1786987013254,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clinph.2020.11.022","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T02:08:37Z","timestamp":1610935717000},"page":"581-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis"],"prefix":"10.1016","volume":"132","author":[{"given":"Mario","family":"Habek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Crno\u0161ija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamari","family":"Junakovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-6526","authenticated-orcid":false,"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Barun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Gabeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Krbot Skori\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinph.2020.11.022_b0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.clinph.2018.05.009","article-title":"Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype","volume":"129","author":"Adamec","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.clinph.2020.11.022_b0010","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinph.2020.11.022_b0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinph.2020.11.022_b0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am Heart J"},{"issue":"105","key":"10.1016\/j.clinph.2020.11.022_b0025","first-page":"24","article-title":"Decreased maximal heart rate with aging is related to reduced {beta}-adrenergic responsiveness but is largely explained by a reduction in intrinsic heart rate","volume":"2008","author":"Christou","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.clinph.2020.11.022_b0030","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinph.2020.11.022_b0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: pooled safety data from three phase 3 studies","volume":"3","author":"DiMarco","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinph.2020.11.022_b0045","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinph.2020.11.022_b0050","article-title":"Adrenergic hyperactivity: a missing link between multiple sclerosis and cardiovascular comorbidities?","author":"Habek","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.clinph.2020.11.022_b0055","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1007\/s10072-020-04432-3","article-title":"The association between the adrenergic hyperactivity and blood pressure values in people with multiple sclerosis","volume":"41","author":"Habek","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinph.2020.11.022_b0060","doi-asserted-by":"crossref","first-page":"e0132139","DOI":"10.1371\/journal.pone.0132139","article-title":"Central autonomic dysfunction delays recovery of fingolimod induced heart rate slowing","volume":"10","author":"Hilz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinph.2020.11.022_b0065","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2020.11.022_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.msard.2018.11.006","article-title":"Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?","volume":"27","author":"Kocyigit","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinph.2020.11.022_b0075","doi-asserted-by":"crossref","first-page":"23722","DOI":"10.1074\/jbc.273.37.23722","article-title":"Molecular cloning and functional characterization of murine sphingosine kinase","volume":"273","author":"Kohama","year":"1998","journal-title":"J Biol Chem"},{"issue":"12 Pt 1","key":"10.1016\/j.clinph.2020.11.022_b9005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0895-7061(96)00249-X","article-title":"Association of cardiac autonomic function and the development of hypertension: the ARIC study","volume":"9","author":"Liao","year":"1996","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.clinph.2020.11.022_b0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2741\/4458","article-title":"Implication of sphingosin-1-phosphate in cardiovascular regulation","volume":"21","author":"Li","year":"2016","journal-title":"Front Biosci (Landmark Ed)."},{"key":"10.1016\/j.clinph.2020.11.022_b0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0025-6196(12)60631-4","article-title":"Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure","volume":"68","author":"Low","year":"1993","journal-title":"Mayo Clin Proc"},{"issue":"83","key":"10.1016\/j.clinph.2020.11.022_b0095","first-page":"278","article-title":"Defining the clinical course of multiple sclerosis: the revisions","volume":"2014","author":"Lublin","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.clinph.2020.11.022_b9000","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458512437814","article-title":"CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia","volume":"18","author":"Marrie","year":"2012","journal-title":"Mult Scler."},{"key":"10.1016\/j.clinph.2020.11.022_b0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","article-title":"Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","volume":"17","author":"Malik","year":"1996","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.clinph.2020.11.022_b0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40263-016-0340-9","article-title":"Secondary progressive multiple sclerosis: definition and measurement","volume":"30","author":"Plantone","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinph.2020.11.022_b0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1352458514538885","article-title":"The autonomic balance predicts cardiac responses after the first dose of fingolimod","volume":"21","author":"Rossi","year":"2015","journal-title":"Mult Scler J"},{"key":"10.1016\/j.clinph.2020.11.022_b0115","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinph.2020.11.022_b0120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1476-5381.2011.01260.x","article-title":"Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system","volume":"163","author":"Schuchardt","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinph.2020.11.022_b0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fpubh.2017.00258","article-title":"An overview of heart rate variability metrics and norms","volume":"5","author":"Shaffer","year":"2017","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinph.2020.11.022_b0130","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3389\/fpsyg.2014.01040","article-title":"A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability","volume":"5","author":"Shaffer","year":"2014","journal-title":"Front Psychol"},{"key":"10.1016\/j.clinph.2020.11.022_b0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbalip.2008.04.003","article-title":"Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system","volume":"1781","author":"Takuwa","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinph.2020.11.022_b0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cmpb.2013.07.024","article-title":"Kubios HRV\u2013heart rate variability analysis software","volume":"113","author":"Tarvainen","year":"2014","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clinph.2020.11.022_b0145","doi-asserted-by":"crossref","first-page":"116423","DOI":"10.1016\/j.jns.2019.116423","article-title":"Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod","volume":"405","author":"Vanoli","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2020.11.022_b0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ane.12573","article-title":"Early safety and efficacy of fingolimod treatment in Denmark","volume":"135","author":"Voldsgaard","year":"2017","journal-title":"Acta Neurol Scand"}],"container-title":["Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245720305836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245720305836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:03:48Z","timestamp":1761393828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245720305836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1388245720305836"],"URL":"https:\/\/doi.org\/10.1016\/j.clinph.2020.11.022","relation":{},"ISSN":["1388-2457"],"issn-type":[{"value":"1388-2457","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinph.2020.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}